GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Cash And Cash Equivalents

XTL Biopharmaceuticals (XTAE:XTLB) Cash And Cash Equivalents : ₪3.96 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Cash And Cash Equivalents?

XTL Biopharmaceuticals's quarterly cash and cash equivalents declined from Sep. 2023 (₪5.41 Mil) to Dec. 2023 (₪5.20 Mil) but then stayed the same from Dec. 2023 (₪5.20 Mil) to Mar. 2024 (₪3.96 Mil).

XTL Biopharmaceuticals's annual cash and cash equivalents declined from Dec. 2021 (₪11.02 Mil) to Dec. 2022 (₪7.77 Mil) and declined from Dec. 2022 (₪7.77 Mil) to Dec. 2023 (₪5.20 Mil).

XTL Biopharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for XTL Biopharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Cash And Cash Equivalents Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.53 13.47 11.02 7.77 5.20

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.07 5.90 5.41 5.20 3.96

XTL Biopharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

XTL Biopharmaceuticals  (XTAE:XTLB) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

XTL Biopharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Cash And Cash Equivalents
Comparable Companies
XTAE:CANF XTAE:PPBT XTAE:CBI XTAE:MTLF XTAE:KDST XTAE:BOLT XTAE:PLNT XTAE:HDST-M XTAE:DNA XTAE:GFC-M OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XTLB:USA H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.